Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pet Pharm Biotech CoROCO:7762 +0.20%19 FCF Margin % is 91.73% as of Dec. 2025. GuruFocus rates ROCO:7762 with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 961 Drug Manufacturers companies, Pet Pharm Biotech Co ranks worse than 52.34% on this metric.
The historical rank and industry rank for Pet Pharm Biotech Co's FCF Margin % or its related term are showing as below:
ROCO:7762'
s FCF Margin % Range Over the Past 10 Years
Min: -122.87 Med: -17.41 Max: 6.85
Current: 1.99
During the past 4 years, the highest FCF Margin % of Pet Pharm Biotech Co was 6.85%. The lowest was -122.87%. And the median was -17.41%.
ROCO:7762's FCF Margin % is ranked worse than 52.34% of 961
companies
in the Drug Manufacturers industry
Industry Median: 2.59
vs ROCO:7762: 1.99
Pet Pharm Biotech Co FCF Margin % Related Terms
Pet Pharm Biotech Co FCF Margin % Historical Data
* Premium members only.
The historical data trend for Pet Pharm Biotech Co's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7762 vs LLY, JNJ, ABBV: FCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pet Pharm Biotech Co FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Pet Pharm Biotech Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pet Pharm Biotech Co (ROCO:7762) has a FCF Margin % of 91.73% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Pet Pharm Biotech Co and its competitors. According to the industry distribution chart, Pet Pharm Biotech Co ranks #503 out of 961 companies in the Drug Manufacturers industry, placing it in the top 52.3%.
Is Pet Pharm Biotech Co's FCF Margin % too high?
Pet Pharm Biotech Co's current FCF Margin % is 91.73%. The Drug Manufacturers industry median FCF Margin % is 2.59. Pet Pharm Biotech Co's value of 91.73% is 3441.7% above this industry median. Based on the distribution chart, Pet Pharm Biotech Co ranks #503 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Pet Pharm Biotech Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's FCF Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Pet Pharm Biotech Co ranks #503 out of 961 companies for FCF Margin %. This places Pet Pharm Biotech Co in the lower half of its industry. The industry median FCF Margin % is 2.59. Pet Pharm Biotech Co's value of 91.73% is 3441.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.59, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pet Pharm Biotech Co's current FCF Margin % of 91.73% is 3441.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Pet Pharm Biotech Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pet Pharm Biotech Co's current FCF Margin % is 91.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current FCF Margin % of 91.73%. The current FCF Margin % is 91.73% and 3441.7% above the Drug Manufacturers industry median of 2.59. Pet Pharm Biotech Co's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current FCF Margin % is 91.73% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
19GF Score
Get the complete analysis for ROCO:7762
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7762 has been successfully added to your 
